Bambusa Therapeutics and Aspen Neuroscience began trading after their IPOs, with both stocks opening below their IPO prices amid broader Nasdaq weakness. The public debut comes as investors remain cautious around tech and biotech valuation dynamics. Bambusa and Aspen each faced double-digit percentage declines earlier in the first day before recovering from the lows. Bambusa’s fundraising is described as aimed at funding immunology-focused antibody programs, while Aspen is preparing for a pivotal test of its Parkinson’s disease cell therapy. The IPO pricing and first-day reaction reflect continued public-market selectivity for biotech assets, especially for companies tied to long development cycles. The next phase for both firms is less about trading performance and more about advancing program catalysts and clinical execution—timelines that will be closely tracked by public investors.